<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Imugene Limited (ASX:IMU, OTC:IUGNF) has advanced another treatment in its development pipeline through a clinical trial supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc (NYSE:PFE) to evaluate the safety and efficacy of Imugene’s HER-Vaxx, in combination with avelumab, in patients with HER-2 positive gastric cancer. HER-Vaxx is Imugene’s B-cell activating immunotherapy, which will be assessed in conjunction with avelumab, an immune checkpoint inhibitor targeting PD-L1 which is marketed as BAVENCIO® and co-developed and commercialised by Merck KGaA and Pfizer.
...read full article on Proactive Investors
